Category: Esophagus Cancer

Theliatinib tartrate is an Orally Active EGFR Inhibitor for Esophageal Cancer Research

EGFR stands for epidermal growth factor receptor, a tyrosine kinase and transmembrane receptor protein. It primarily functions to regulate epithelial tissue development and homeostasis. Moreover, EGFR is a driver of tumors. Specifically, it is often abnormally activated and overexpressed in cancer cells (such as esophageal cancer). EGFR selectively binds...

Conglobatin, an Orally Active Hsp90 Inhibitor, Disrupts Hsp90-Cdc37 Complex Formation

Heat shock protein (Hsp) 90 is a chaperone protein. In addition to protecting cells by correcting misfolded proteins, Hsp90 also plays a key role in regulating the stability, maturation, and activation of a wide range of client substrates, including kinases, hormone receptors, and transcription factors. Most Hsp90 client proteins,...

IACS-13909 is a Selective and Orally Active SHP2 Inhibitor

Src homology 2 domain-containing phosphatase (SHP2) is a phosphatase that mediates signaling downstream of multiple receptor tyrosine kinases. SHP2 suppresses signaling through the MAPK pathway. Furthermore, SHP2 inhibition has demonstrated tumor growth inhibition in receptor tyrosine kinases-activated cancers. In this study, researchers report the discovery of IACS-13909. IACS-13909 is...